The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis

Abstract Background An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. Methods A meta-analysis was performed to assess the correlation bet...

Full description

Bibliographic Details
Main Authors: Lilong Zhang, Qihang Yuan, Man Li, Dongqi Chai, Wenhong Deng, Weixing Wang
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-020-07651-1
id doaj-1576e8d6449d4757ae9ce10008c68610
record_format Article
spelling doaj-1576e8d6449d4757ae9ce10008c686102020-12-06T12:54:15ZengBMCBMC Cancer1471-24072020-11-0120112010.1186/s12885-020-07651-1The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysisLilong Zhang0Qihang Yuan1Man Li2Dongqi Chai3Wenhong Deng4Weixing Wang5Department of General Surgery, Renmin Hospital of Wuhan UniversityDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical UniversityDepartment of General Surgery, Renmin Hospital of Wuhan UniversityDepartment of General Surgery, Renmin Hospital of Wuhan UniversityDepartment of General Surgery, Renmin Hospital of Wuhan UniversityDepartment of General Surgery, Renmin Hospital of Wuhan UniversityAbstract Background An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. Methods A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. Results Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). Conclusion The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis.https://doi.org/10.1186/s12885-020-07651-1LeptinAdiponectinHepatocellular carcinomaMeta-analysis
collection DOAJ
language English
format Article
sources DOAJ
author Lilong Zhang
Qihang Yuan
Man Li
Dongqi Chai
Wenhong Deng
Weixing Wang
spellingShingle Lilong Zhang
Qihang Yuan
Man Li
Dongqi Chai
Wenhong Deng
Weixing Wang
The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
BMC Cancer
Leptin
Adiponectin
Hepatocellular carcinoma
Meta-analysis
author_facet Lilong Zhang
Qihang Yuan
Man Li
Dongqi Chai
Wenhong Deng
Weixing Wang
author_sort Lilong Zhang
title The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_short The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_full The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_fullStr The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_full_unstemmed The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_sort association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2020-11-01
description Abstract Background An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. Methods A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. Results Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). Conclusion The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis.
topic Leptin
Adiponectin
Hepatocellular carcinoma
Meta-analysis
url https://doi.org/10.1186/s12885-020-07651-1
work_keys_str_mv AT lilongzhang theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT qihangyuan theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT manli theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT dongqichai theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT wenhongdeng theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT weixingwang theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT lilongzhang associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT qihangyuan associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT manli associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT dongqichai associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT wenhongdeng associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT weixingwang associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
_version_ 1724398475523653632